The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
To evaluate the cross-talk between BRCA1-IRIS (IRIS)-overexpressing (IRISOE) TNBC cells and tumor-resident mesenchymal stem cells (MSCs) that triggers the aggressiveness or elimination of IRISOE TNBC tumors. We analyzed the effect of silencing or inactivating IRIS on the bi-directional interaction between IRISOE TNBC cells and MSCs on tumor formation and progression. We analyzed the downstream signaling in MSCs induced by IL-6 secreted from IRISOE TNBC cells. We compared the effect of MSCs on the formation and progression of IRIS-proficient and deficient-TNBC cells/tumors using in vitro and in vivo models. Finally, we analyzed the association between IL-6, PTGER2, and PTGER4 overexpression and breast cancer subtype; hormone receptor status; and distant metastasis-free or overall survival. We show high-level IL-6 secreted from IRISOE TNBC cells that enhances expression of its receptor (IL-6R) in MSCs, their proliferation, and migration toward IRISOE, in vitro, and recruitment into IRISOE TNBC tumors, in vivo. In serum-free medium, recombinant IL-6 and the IL-6-rich IRISOE TNBC cell condition media (CM) decreased STAT3 Y705 phosphorylation (p-STAT3 Y705 ) in MSCs. Inhibiting IRIS expression or activity prolonged STAT3 Y705 phosphorylation in MSCs. The interaction with IRISOE TNBC cells skewed MSC differentiation toward prostaglandin E 2 (PGE 2 )-secreting pro-aggressiveness cancer-associated fibroblasts (CAFs). Accordingly, co-injecting human or mouse MSCs with IRISOE TNBC tumor cells promoted the formation of aggressive mammary tumors, high circulating IL-6 and PGE 2 levels, and reduced overall survival. In contrast, IRIS-silenced or inactivated cells showed reduced tumor formation ability, limited MSC recruitment into tumors, reduced circulating IL-6 and PGE 2 levels, and prolonged overall survival. A positive correlation between IL-6, PTGER2, and PTGER4 expression and basal phenotype; ER-negativity; distant metastasis-free and overall survival in basal; or BRCA mutant carriers was observed. Finally, the bi-directional interaction with MSCs triggered death rather than growth of IRIS-silenced TNBC cells, in vitro and in vivo. The IL-6/PGE 2 -positive feedback loop between IRISOE TNBC tumor cells and MSCs enhances tumor aggressiveness. Inhibiting IRIS expression limits TNBC tumor growth and progression through an MSC-induced death of IRIS-silenced/inactivated TNBC cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 IL-6/PGE2 feedback loop between IRISOE TNBC cells and activated MSCs. a Normalized IL-6 level detected using ELISA in CM of HME, IRIS291, and IRIS293 cells expressing siLuc or siHIF-1α exposed 24 h to normoxic or hypoxic conditions. Experiments were done three separate times in triplicates. b Expression of indicated proteins in MSCs exposed to CM from IRIS291, IRIS292, or IRIS293 cells grown under normoxic or hypoxic condition added plus vehicle or anti-IL-6 NeuAb. Fold change in black compares normoxic and hypoxic conditions, and in red compares hypoxia plus vehicle vs. plus IL-6 NeuAb conditions. Experiments were done at least twice. c Top: effects of 10 μM of STAT3 inhibitor; VII, PI3’K/AKT inhibitor; LY294002 and ERK inhibitor; PD98059 on their cognate kinase. Bottom: MTS assay measuring proliferation of MSCs exposed to CM from normoxic or hypoxic IRIS291 or IRIS293 in the presence of vehicle, VII, LY294002, or PD98059. Experiments were done three separate times in triplicates. The level of p-STAT3Y705 in MSCs exposed to vehicle [−] or 30 ng/ml rIL-6 or CM from HME, IRIS291, IRIS292, or IRIS293 cells for 30 min (d), or CM from MDA-231 or MDA-468 expressing si/shCtrl or si/shIRIS or MCF7 or T47D expressing vector or IRIS cDNA for 30 min (e). d, e Experiments were done at least twice. f The level of p-STAT3Y705, total STAT3 or Cyclin D1 in cytoplasm (C) or nuclear/chromatin (N + Ch) fractions of MSCs exposed to vehicle [−] or 30 ng/ml rIL-6 or CM from MDA-231, MDA-468, or MDA-453 expressing si/shCtrl or si/shIRIS for 30 min. Experiments were done at least twice. g Fluorescence IHC for p-STAT3Y705 and CD105 on sections from the core (1–4) or periphery (5–8) of IRIS291 tumors. Scale bar = 100 μm. h Migration in Boyden chambers of MSCs layered in inserts and exposed to HME (1) or IRISOE cells CM plus vehicle (2) or plus IL-6 NeuAb (3). Experiments were done in triplicates three separate times. i Migration in Boyden chambers of MSCs layered in the inserts exposed to vehicle [−], IRIS291 or IRIS293 cell CM containing vehicle, VII, LY294002, or PD98059 (at 10 μM each). Experiments were done three separate times in triplicates. j Inset: normalized PGE2 level secreted from naïve MSCs, HME, IRIS291, or IRIS293 cells as detected using ELISA. Experiments were done three separate times in triplicates. Normalized PGE2 levels secreted from naïve MSCs or MSCs exposed to CM from HME, IRIS291, or IRIS293 cells expressing (48 h) siLuc or siIL-6 and exposed (24 h) to normoxia or hypoxia as detected using ELISA. Experiments were done three separate times in triplicates. k The level of EP2 and EP4 in HME, IRIS291, IRIS292, or IRIS293 cells. Experiments were done at least twice. l Schematic representation of the data represented above](https://figures.cochat.ai/paper-figures/2bd40aea62c940de8c6d6ad1cf7c9edf/the-pro-and-anti-tumor-roles-of-mesenchymal-stem-cells-toward-brca1-iris-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Many studies have con fi rmed the interaction between MSCs and breast cancer cells [44,45].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Prostanoid Receptors: Structures, Properties, and Functions
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1193 · Cited by 2,412
Quante, M., Tu, S. P., Tomita, H., Gonda, T., Wang, S. S. W., Takashi, S., Baik, G. H., Shibata, W., DiPrete, B., Betz, K. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.020 · Cited by 1,044
Apoptosis, autophagy, necroptosis, and cancer metastasis
Su, Z., Yang, Z., Xu, Y., Chen, Y., & Yu, Q. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0321-5 · Cited by 1,042
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912
IL-6: From its discovery to clinical applications
Kishimoto, T. (2010) · International Immunology · doi:10.1093/intimm/dxq030 · Cited by 846
How mesenchymal stem cells interact with tissue immune responses
Shi, Y., Su, J., Roberts, A. I., Shou, P., Rabson, A. B., & Ren, G. (2012) · Trends in Immunology · doi:10.1016/j.it.2011.11.004 · Cited by 633
Aoki, Y., Feldman, G. M., & Tosato, G. (2003) · Blood · doi:10.1182/blood-2002-07-2130 · Cited by 438
Research works printed but not linked: 1
- Sinha A, Paul BT, Sullivan LM, Sims H, El Bastawisy A, Yousef HF, Zekri AN, Bahnassy AA, ElShamy WM. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget. 2017;8(6):10114–35. · DOI
Cited by
3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions
Rodrigues, J., Heinrich, M. A., Teixeira, L. M., & Prakash, J. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2020.10.009 · Cited by 405
Kulesza, A., Paczek, L., & Burdzinska, A. (2023) · Biomedicines · doi:10.3390/biomedicines11020445 · Cited by 163
Hill, B. S., Sarnella, A., D’Avino, G., & Zannetti, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.028 · Cited by 156
Simon, T., & Salhia, B. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0282 · Cited by 108
“Bone marrow–derived MSCs have been proposed by our group and others to also be the source of tumor-inhibitory CAFs (9, 61).”
BackgroundSami, E., Paul, B. T., Koziol, J. A., & ElShamy, W. M. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2374 · Cited by 96
“We recently named this core “the aggressiveness niche” (20), and showed experimental evidence that IRISOE TNBC metastatic precursors develop within this aggressiveness niche (19,21,22).”
BackgroundSelf-citation
Metadata
- Authors
- Ryan, D., Paul, B. T., Koziol, J., & ElShamy, W. M.
- Affiliations
- San Diego Biomedical Research Institute (US)
- UConn Health (US)
- Scripps Research Institute (US)
- Corresponding author
- ElShamy, Wael M.
- Venue
- Breast Cancer Research
- Published
- 2019-04-24
- Volume
- 21
- Issue
- 1
- Pages
- 53-53
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- PMC
- PMC6480921
- OpenAlex
- W2946750486
- Cited by
- 25
- References
- 77
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 2 · 2019: 2
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Breast Cancer Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Cancer Institute (R01 CA194447)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- mesenchymal stem cells, triple-negative breast cancer, iris, interleukin-6, IL-6 receptor, STAT3 phosphorylation, prostaglandin E2, EP2 receptor, EP4 receptor, cancer-associated fibroblasts, tumor microenvironment, tumor progression, overall survival, BRCA1 mutation carriers
- MeSH terms
- Animals, Disease Models, Animal, Female, Humans, Models, Biological, Prognosis, Biomarkers, Tumor, Dinoprostone, Interleukin-6, Gene Expression Regulation, Neoplastic, Alternative Splicing, BRCA1 Protein, Cell Line, Tumor, Mice, Gene Knockdown Techniques, Mesenchymal Stem Cells, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells. https://app.cochat.ai/papers/10.1186/s13058-019-1131-2
- The paper
- Ryan, D., Paul, B. T., Koziol, J., & ElShamy, W. M. (2019). The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells. Breast Cancer Research. https://doi.org/10.1186/s13058-019-1131-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.